167 related articles for article (PubMed ID: 33552662)
1. Advanced Practice Perspectives on Preventing and Managing Tumor Lysis Syndrome and Neutropenia in Chronic Lymphocytic Leukemia.
Goodrich A
J Adv Pract Oncol; 2021; 12(1):59-70. PubMed ID: 33552662
[TBL] [Abstract][Full Text] [Related]
2. Real-world incidence of venetoclax toxicities in British Columbia.
Lee C; Markarian A; Ladha F; Nakashima L; de Lemos M; Schaff K; Woo S; Gerrie A
J Oncol Pharm Pract; 2022 Jul; 28(5):1163-1169. PubMed ID: 35253497
[TBL] [Abstract][Full Text] [Related]
3. A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Ozturk E; Erdogan Ozunal I
Medeni Med J; 2021; 36(2):176-179. PubMed ID: 34239769
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.
Coiffier B; Altman A; Pui CH; Younes A; Cairo MS
J Clin Oncol; 2008 Jun; 26(16):2767-78. PubMed ID: 18509186
[TBL] [Abstract][Full Text] [Related]
5. Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
Cheson BD
Clin Adv Hematol Oncol; 2009 Apr; 7(4):263-71. PubMed ID: 19521331
[TBL] [Abstract][Full Text] [Related]
6. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
[TBL] [Abstract][Full Text] [Related]
7. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.
Cheson BD; Frame JN; Vena D; Quashu N; Sorensen JM
J Clin Oncol; 1998 Jul; 16(7):2313-20. PubMed ID: 9667245
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.
Cairo MS; Coiffier B; Reiter A; Younes A;
Br J Haematol; 2010 May; 149(4):578-86. PubMed ID: 20331465
[TBL] [Abstract][Full Text] [Related]
9. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.
Howard SC; Trifilio S; Gregory TK; Baxter N; McBride A
Ann Hematol; 2016 Mar; 95(4):563-73. PubMed ID: 26758269
[TBL] [Abstract][Full Text] [Related]
10. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel.
Perissinotti AJ; Bishop MR; Bubalo J; Geyer MB; Goodrich A; Howard SC; Kula J; Mandayam S; Cairo MS; Pui CH
Cancer Treat Rev; 2023 Nov; 120():102603. PubMed ID: 37579533
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
.
Brumbaugh Paradis H; Alter D; Llerandi D
Clin J Oncol Nurs; 2017 Oct; 21(5):604-610. PubMed ID: 28945711
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax for the treatment of chronic lymphocytic leukemia.
Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F
Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395
[TBL] [Abstract][Full Text] [Related]
13. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature.
Hussain K; Mazza JJ; Clouse LH
Am J Hematol; 2003 Mar; 72(3):212-5. PubMed ID: 12605395
[TBL] [Abstract][Full Text] [Related]
14. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.
Mughal TI; Ejaz AA; Foringer JR; Coiffier B
Cancer Treat Rev; 2010 Apr; 36(2):164-76. PubMed ID: 20031331
[TBL] [Abstract][Full Text] [Related]
15. Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel.
Pession A; Masetti R; Gaidano G; Tosi P; Rosti G; Aglietta M; Specchia G; Porta F; Pane F
Adv Ther; 2011 Aug; 28(8):684-97. PubMed ID: 21779956
[TBL] [Abstract][Full Text] [Related]
16. A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies.
Sharman JP; Biondo JML; Boyer M; Fischer K; Hallek M; Jiang D; Kater AP; Porro Lurà M; Wierda WG
EJHaem; 2022 May; 3(2):492-506. PubMed ID: 35846043
[TBL] [Abstract][Full Text] [Related]
17. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
18. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
[No Abstract] [Full Text] [Related]
20. Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
Calvo-Villas JM; Urcuyo BM; Umpierrez AM; Sicilia F
Onkologie; 2008 Apr; 31(4):197-9. PubMed ID: 18418022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
